Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome

The immunological function of CD52 and its targeting in organ transplantation

(2017) Yang Zhao et al.   INFLAMMATION RESEARCH

Impact of Serotherapy on Immune Reconstitution and Survival Outcomes After Stem Cell Transplantations in Children: Thymoglobulin Versus Alemtuzumab

(2015) Laura Willemsen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT

(2015) R. A. Marsh et al.   BLOOD

Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis

(2015) Rick Admiraal et al.   Lancet Haematology

Population Pharmacokinetic Modeling of Thymoglobulin® in Children Receiving Allogeneic-Hematopoietic Cell Transplantation: Towards Improved Survival Through Individualized Dosing

(2014) Rick Admiraal et al.   CLINICAL PHARMACOKINETICS

Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling

(2013) Rick Admiraal et al.   ARCHIVES OF DISEASE IN CHILDHOOD

Low-Dose Serotherapy Improves Early Immune Reconstitution after Cord Blood Transplantation for Primary Immunodeficiencies

(2013) Jonathan P. Lane et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A Novel Maturation Function for Clearance of the Cytochrome P450 3A Substrate Midazolam from Preterm Neonates to Adults

(2013) Ibrahim Ince et al.   CLINICAL PHARMACOKINETICS

Serum Adalimumab Concentration and Clinical Remission in Patients with Crohnʼs Disease

(2013) Yi-Lin Chiu et al.   INFLAMMATORY BOWEL DISEASES

T cell depletion in paediatric stem cell transplantation

(2012) C. Booth et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Body Weight-Dependent Pharmacokinetics of Busulfan in Paediatric Haematopoietic Stem Cell Transplantation Patients

(2012) Imke H. Bartelink et al.   CLINICAL PHARMACOKINETICS

Maturation of the Glomerular Filtration Rate in Neonates, as Reflected by Amikacin Clearance

(2012) Roosmarijn F.W. De Cock et al.   CLINICAL PHARMACOKINETICS

The Combination of Exposure-Response and Case-Control Analyses in Regulatory Decision Making

(2012) Jun Yang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A Bodyweight-Dependent Allometric Exponent for Scaling Clearance Across the Human Life-Span

(2012) Chenguang Wang et al.   PHARMACEUTICAL RESEARCH

Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies

(2011) R. J. Soiffer et al.   BLOOD

IgG antibodies to ATG early after pediatric hematopoietic SCT increase the risk of acute GVHD

(2011) C M Jol-van der Zijde et al.   BONE MARROW TRANSPLANTATION

Alemtuzumab in allogeneic hematopoetic stem cell transplantation

(2011) Xavier Poiré et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Alemtuzumab for the prevention and treatment of graft-versus-host disease

(2011) Junya Kanda et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Individualized dosing regimens in children based on population PKPD modelling: Are we ready for it?

(2011) Catherijne A.J. Knibbe et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies

(2010) Diane R. Mould et al.   BIODRUGS

Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study of the British Society for Blood and Marrow Transplantation

(2010) Gordon Cook et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution

(2010) R. Chakraverty et al.   BLOOD

Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemia

(2010) A Spyridonidis et al.   BONE MARROW TRANSPLANTATION

Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia

(2010) William G. Wierda et al.   CANCER

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Ron J. Keizer et al.   CLINICAL PHARMACOKINETICS

Systematic Evaluation of the Descriptive and Predictive Performance of Paediatric Morphine Population Models

(2010) Elke H. J. Krekels et al.   PHARMACEUTICAL RESEARCH

Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes

(2009) Koen Van Besien et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Morphine Glucuronidation in Preterm Neonates, Infants and Children Younger than 3 Years

(2009) Catherijne A.J. Knibbe et al.   CLINICAL PHARMACOKINETICS

Selection between Michaelis–Menten and target-mediated drug disposition pharmacokinetic models

(2009) Xiaoyu Yan et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML

(2008) R K Malladi et al.   BONE MARROW TRANSPLANTATION

Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R

(2008) Emmanuelle Comets et al.   COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE

Approximations of the target-mediated drug disposition model and identifiability of model parameters

(2008) Leonid Gibiansky et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Pharmacokinetics of alemtuzumab and the relevance in clinical practice

(2008) Thomas Elter et al.   LEUKEMIA & LYMPHOMA